Literature DB >> 21185496

Cerebral embolism following transcatheter aortic valve implantation: comparison of transfemoral and transapical approaches.

Josep Rodés-Cabau1, Eric Dumont, Robert H Boone, Eric Larose, Rodrigo Bagur, Ronen Gurvitch, Fernand Bédard, Daniel Doyle, Robert De Larochellière, Cleonie Jayasuria, Jacques Villeneuve, Alier Marrero, Mélanie Côté, Philippe Pibarot, John G Webb.   

Abstract

OBJECTIVES: The objective of this study was to compare the incidence of cerebral embolism (CE) as evaluated by diffusion-weighted magnetic resonance imaging (DW-MRI) following transapical (TA) transcatheter aortic valve implantation (TAVI) versus transfemoral (TF) TAVI.
BACKGROUND: The TA-TAVI approach avoids both the manipulation of large catheters in the aortic arch/ascending aorta and the retrograde crossing of the aortic valve, and this avoidance might lead to a lower rate of CE.
METHODS: This was a prospective multicenter study including 60 patients who underwent cerebral DW-MRI the day before and within the 6 days following TAVI (TF approach: 29 patients; TA approach: 31 patients). Neurologic and cognitive function assessments were performed at DW-MRI time points.
RESULTS: The TAVI procedure was performed with the Edwards valve and was successful in all cases but one (98%). A total of 41 patients (68%) had 251 new cerebral ischemic lesions at the DW-MRI performed 4 ± 1 days after the procedure, 19 patients in the TF group (66%) and 22 patients in the TA group (71%; p = 0.78). Most patients (76%) with new ischemic lesions had multiple lesions (median number of lesions per patient: 3, range 1 to 31). There were no differences in lesion number and size between the TF and TA groups. No baseline or procedural factors were found to be predictors of new ischemic lesions. The occurrence of CE was not associated with a measurable impairment in cognitive function, but 2 patients (3.3%) had a clinically apparent stroke within the 24 h following the procedure (1 patient in each group).
CONCLUSIONS: TAVI is associated with a high rate of silent cerebral ischemic lesions as evaluated by DW-MRI, with no differences between the TF and TA approaches. These results provide important novel insight into the mechanisms of CE associated with TAVI and support the need for further research to both reduce the incidence of CE during these procedures and better determine their clinical relevance.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21185496     DOI: 10.1016/j.jacc.2010.07.036

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  56 in total

Review 1.  Cerebral embolic protection devices during transcatheter aortic valve implantation: clinical versus silent embolism.

Authors:  Luis Nombela-Franco; German Armijo; Gabriela Tirado-Conte
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

2.  Transapical aortic valve implantation: a reasonable therapeutic option, but not the only alternative to transfemoral approach.

Authors:  Stephane Noble
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

3.  Interventional cardiology: TAVI-transcatheter approach choice does not affect cerebral embolisms.

Authors:  Bryony M Mearns
Journal:  Nat Rev Cardiol       Date:  2011-03       Impact factor: 32.419

Review 4.  Vascular access in transcatheter aortic valve implantation.

Authors:  Vasco da Gama Ribeiro; Luis Vouga; Alan Markowitz; Hiram G Bezerra; Pedro Braga; Muhammad Ansari; Daniel Leite; Joao Rocha; Monica Carvalho; Daniel I Simon; Marco A Costa
Journal:  Int J Cardiovasc Imaging       Date:  2011-08-31       Impact factor: 2.357

5.  Influence of continuously evolving transcatheter aortic valve implantation technology on cerebral oxygenation.

Authors:  Ward Eertmans; Cornelia Genbrugge; Tom Fret; Maud Beran; Kim Engelen; Herbert Gutermann; Margot Vander Laenen; Willem Boer; Bert Ferdinande; Frank Jans; Jo Dens; Cathy De Deyne
Journal:  J Clin Monit Comput       Date:  2016-12-26       Impact factor: 2.502

6.  Delayed Coronary Obstruction After Transcatheter Aortic Valve Implantation is not the Structural Equivalent of Late Stent Thrombosis After Percutaneous Coronary Intervention.

Authors:  Simon Kennon
Journal:  Interv Cardiol       Date:  2018-05

Review 7.  TAVI 2012: state of the art.

Authors:  Jochen Reinöhl; Constantin von Zur Mühlen; Martin Moser; Stefan Sorg; Christoph Bode; Manfred Zehender
Journal:  J Thromb Thrombolysis       Date:  2013-05       Impact factor: 2.300

Review 8.  Incidence, predictors, origin and prevention of early and late neurological events after transcatheter aortic valve implantation (TAVI): a comprehensive review of current data.

Authors:  Philipp Kahlert; Fadi Al-Rashid; Björn Plicht; Heike Hildebrandt; Polykarpos Patsalis; Karim El Chilali; Daniel Wendt; Matthias Thielmann; Lars Bergmann; Eva Kottenberg; Marc Schlamann; Holger Eggebrecht; Heinz Jakob; Gerd Heusch; Thomas Konorza; Raimund Erbel
Journal:  J Thromb Thrombolysis       Date:  2013-05       Impact factor: 2.300

Review 9.  Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies.

Authors:  Ziad Sergie; Thierry Lefèvre; Eric Van Belle; Socrates Kakoulides; Usman Baber; Efthymios N Deliargyris; Roxana Mehran; Eberhard Grube; Jochen Reinöhl; George D Dangas
Journal:  J Thromb Thrombolysis       Date:  2013-05       Impact factor: 2.300

10.  A prospective, non-randomized comparison of SAPIEN XT and CoreValve implantation in two sequential cohorts of patients with severe aortic stenosis.

Authors:  Albert Markus Kasel; Salvatore Cassese; Thomas Ischinger; Alexander Leber; Diethmar Antoni; Gotthard Riess; Jayshree Vogel; Adnan Kastrati; Walter Eichinger; Ellen Hoffmann
Journal:  Am J Cardiovasc Dis       Date:  2014-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.